103 related articles for article (PubMed ID: 20831362)
1. Update on lymphocyte specific kinase inhibitors: a patent survey.
Martin MW; Machacek MR
Expert Opin Ther Pat; 2010 Nov; 20(11):1573-93. PubMed ID: 20831362
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
4. Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection.
Kamens JS; Ratnofsky SE; Hirst GC
Curr Opin Investig Drugs; 2001 Sep; 2(9):1213-9. PubMed ID: 11717807
[TBL] [Abstract][Full Text] [Related]
5. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
[TBL] [Abstract][Full Text] [Related]
6. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of lck and loss of TCR-mediated signaling upon persistent engagement with complexes of peptide:MHC molecules.
Lee JE; Cossoy MB; Chau LA; Singh B; Madrenas J
J Immunol; 1997 Jul; 159(1):61-9. PubMed ID: 9200439
[TBL] [Abstract][Full Text] [Related]
9. Lineage-specific control of superantigen-induced cell death by the protein tyrosine kinase p56(lck).
Penninger JM; Wallace VA; Molina T; Mak TW
J Immunol; 1996 Dec; 157(12):5359-66. PubMed ID: 8955183
[TBL] [Abstract][Full Text] [Related]
10. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
Schnaider T; Somogyi J; Csermely P; Szamel M
Cell Stress Chaperones; 2000 Jan; 5(1):52-61. PubMed ID: 10701840
[TBL] [Abstract][Full Text] [Related]
12. MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.
Mukherjee P; Tinder TL; Basu GD; Gendler SJ
J Leukoc Biol; 2005 Jan; 77(1):90-9. PubMed ID: 15513966
[TBL] [Abstract][Full Text] [Related]
13. Sequestration of CD4-associated Lck from the TCR complex may elicit T cell hyporesponsiveness in nonobese diabetic mice.
Zhang J; Salojin K; Delovitch TL
J Immunol; 1998 Feb; 160(3):1148-57. PubMed ID: 9570528
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
[TBL] [Abstract][Full Text] [Related]
16. Conversion of p56(lck) to p60(lck) in human peripheral blood T lymphocytes is dependent on co- stimulation through accessory receptors: involvement of phospholipase C, protein kinase C and MAP-kinases in vivo.
Schröder AJ; Quehl P; Müller J; Samstag Y
Eur J Immunol; 2000 Feb; 30(2):635-43. PubMed ID: 10671221
[TBL] [Abstract][Full Text] [Related]
17. Chemical inhibitors when timing is critical: a pharmacological concept for the maturation of T cell contacts.
Köhler K; Lellouch AC; Vollmer S; Stoevesandt O; Hoff A; Peters L; Rogl H; Malissen B; Brock R
Chembiochem; 2005 Jan; 6(1):152-61. PubMed ID: 15637666
[TBL] [Abstract][Full Text] [Related]
18. Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice.
Takayama T; Takaoka A; Takahashi S; Takahashi A; Umemiya H; Sato M
Arzneimittelforschung; 2010; 60(5):282-5. PubMed ID: 20533766
[TBL] [Abstract][Full Text] [Related]
19. βig-h3 Represses T-Cell Activation in Type 1 Diabetes.
Patry M; Teinturier R; Goehrig D; Zetu C; Ripoche D; Kim IS; Bertolino P; Hennino A
Diabetes; 2015 Dec; 64(12):4212-9. PubMed ID: 26470788
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
